Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This research study is trying to determine the safest dose of Brentuximab Vedotin that can be
given to patients with chronic GVHD and see if chronic GVHD improves.